Annual EBITDA
-$35.03 M
+$1.49 M+4.08%
31 December 2022
Summary:
Zynerba Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$35.03 million, with the most recent change of +$1.49 million (+4.08%) on 31 December 2022. During the last 3 years, it has risen by +$16.82 million (+32.44%).ZYNE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$11.07 M
-$651.00 K-6.25%
30 June 2023
Summary:
Zynerba Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$11.07 million, with the most recent change of -$651.00 thousand (-6.25%) on 30 June 2023.ZYNE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$38.56 M
-$1.96 M-5.34%
30 June 2023
Summary:
Zynerba Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$38.56 million, with the most recent change of -$1.96 million (-5.34%) on 30 June 2023.ZYNE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZYNE EBITDA Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | - | - | - |
3 y3 years | +32.4% | -9.1% | -1.8% |
5 y5 years | +13.1% | -485.7% | -25.1% |
ZYNE EBITDA High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | ||||||
5 y | 5 years | ||||||
alltime | all time | +5888.4% | +4723.7% | >+9999.0% |
Zynerba Pharmaceuticals EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
June 2023 | - | -$11.07 M(+6.2%) | -$38.56 M(+5.3%) |
Mar 2023 | - | -$10.42 M(+20.7%) | -$36.61 M(+4.5%) |
Dec 2022 | -$35.03 M(-4.1%) | -$8.63 M(+2.3%) | -$35.03 M(-0.4%) |
Sept 2022 | - | -$8.44 M(-7.4%) | -$35.17 M(-4.6%) |
June 2022 | - | -$9.11 M(+3.1%) | -$36.88 M(-1.8%) |
Mar 2022 | - | -$8.84 M(+0.8%) | -$37.54 M(+2.8%) |
Dec 2021 | -$36.52 M(-29.6%) | -$8.77 M(-13.5%) | -$36.52 M(-3.6%) |
Sept 2021 | - | -$10.15 M(+3.8%) | -$37.88 M(+2.6%) |
June 2021 | - | -$9.78 M(+25.0%) | -$36.90 M(-24.6%) |
Mar 2021 | - | -$7.82 M(-22.8%) | -$48.92 M(-5.7%) |
Dec 2020 | -$51.86 M(+51.7%) | -$10.13 M(+10.4%) | -$51.86 M(-2.4%) |
Sept 2020 | - | -$9.17 M(-57.9%) | -$53.11 M(+15.9%) |
June 2020 | - | -$21.79 M(+102.6%) | -$45.82 M(+29.1%) |
Mar 2020 | - | -$10.76 M(-5.5%) | -$35.51 M(+3.9%) |
Dec 2019 | -$34.19 M(-15.2%) | -$11.38 M(+502.1%) | -$34.19 M(+10.9%) |
Sept 2019 | - | -$1.89 M(-83.5%) | -$30.83 M(-16.5%) |
June 2019 | - | -$11.48 M(+21.6%) | -$36.90 M(-1.3%) |
Mar 2019 | - | -$9.44 M(+17.7%) | -$37.37 M(-7.3%) |
Dec 2018 | -$40.30 M | -$8.02 M(+0.7%) | -$40.30 M(-0.4%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2018 | - | -$7.96 M(-33.4%) | -$40.46 M(-1.4%) |
June 2018 | - | -$11.95 M(-3.4%) | -$41.02 M(+9.6%) |
Mar 2018 | - | -$12.37 M(+51.2%) | -$37.42 M(+14.3%) |
Dec 2017 | -$32.73 M(+41.5%) | -$8.18 M(-4.1%) | -$32.73 M(+4.9%) |
Sept 2017 | - | -$8.52 M(+2.2%) | -$31.21 M(+8.9%) |
June 2017 | - | -$8.34 M(+8.6%) | -$28.66 M(+7.8%) |
Mar 2017 | - | -$7.68 M(+15.3%) | -$26.59 M(+14.9%) |
Dec 2016 | -$23.13 M(+85.0%) | -$6.66 M(+11.6%) | -$23.13 M(+5.8%) |
Sept 2016 | - | -$5.97 M(-4.8%) | -$21.87 M(+10.0%) |
June 2016 | - | -$6.27 M(+48.3%) | -$19.89 M(+30.5%) |
Mar 2016 | - | -$4.23 M(-21.7%) | -$15.24 M(+21.9%) |
Dec 2015 | -$12.51 M(+121.7%) | -$5.40 M(+35.5%) | -$12.51 M(+47.0%) |
Sept 2015 | - | -$3.99 M(+145.5%) | -$8.51 M(+21.1%) |
June 2015 | - | -$1.62 M(+8.9%) | -$7.03 M(+1.8%) |
Mar 2015 | - | -$1.49 M(+6.3%) | -$6.90 M(+22.4%) |
Dec 2014 | -$5.64 M(+864.2%) | -$1.40 M(-44.1%) | -$5.64 M(+33.1%) |
Sept 2014 | - | -$2.51 M(+67.2%) | -$4.24 M(+145.0%) |
June 2014 | - | -$1.50 M(+553.7%) | -$1.73 M(+653.7%) |
Mar 2014 | - | -$229.50 K | -$229.50 K |
Dec 2013 | -$585.00 K | - | - |
FAQ
- What is Zynerba Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Zynerba Pharmaceuticals?
What is Zynerba Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ZYNE is -$35.03 M
What is the all time high annual EBITDA for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$585.00 K
What is Zynerba Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ZYNE is -$11.07 M
What is the all time high quarterly EBITDA for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$229.50 K
What is Zynerba Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ZYNE is -$38.56 M
What is the all time high TTM EBITDA for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$229.50 K